We demonstrate, for the first time, that CBD enhances oxaliplatin-mediated autophagy via NOS3-mediated mitochondrial dysfunction, suggesting that NOS3 is a potential therapeutic target for overcoming oxaliplatin resistance and that CBD may be a new therapeutic agent for CRC treatment. This evidence concerns the gene NOS3 and colorectal carcinoma.